DE69435155D1 - Zusuammensetzungen zur Behandlung von Krebs mittels Viren - Google Patents

Zusuammensetzungen zur Behandlung von Krebs mittels Viren

Info

Publication number
DE69435155D1
DE69435155D1 DE69435155T DE69435155T DE69435155D1 DE 69435155 D1 DE69435155 D1 DE 69435155D1 DE 69435155 T DE69435155 T DE 69435155T DE 69435155 T DE69435155 T DE 69435155T DE 69435155 D1 DE69435155 D1 DE 69435155D1
Authority
DE
Germany
Prior art keywords
compositions
cancer
viruses
treatment
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69435155T
Other languages
English (en)
Inventor
Robert M Lorence
Kirk W Reichard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Biologics Corp
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Application granted granted Critical
Publication of DE69435155D1 publication Critical patent/DE69435155D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
DE69435155T 1993-04-30 1994-04-29 Zusuammensetzungen zur Behandlung von Krebs mittels Viren Expired - Lifetime DE69435155D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5551993A 1993-04-30 1993-04-30

Publications (1)

Publication Number Publication Date
DE69435155D1 true DE69435155D1 (de) 2008-12-04

Family

ID=21998395

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69432409T Expired - Lifetime DE69432409T2 (de) 1993-04-30 1994-04-29 Verwendung der NDV zur Herstellung eines Medikaments zur Krebsbehandlung
DE69435155T Expired - Lifetime DE69435155D1 (de) 1993-04-30 1994-04-29 Zusuammensetzungen zur Behandlung von Krebs mittels Viren
DE69435118T Expired - Lifetime DE69435118D1 (de) 1993-04-30 1994-04-29 Gereinigte Zusammensetzungen von Newcastle-Krankheitvirus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69432409T Expired - Lifetime DE69432409T2 (de) 1993-04-30 1994-04-29 Verwendung der NDV zur Herstellung eines Medikaments zur Krebsbehandlung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69435118T Expired - Lifetime DE69435118D1 (de) 1993-04-30 1994-04-29 Gereinigte Zusammensetzungen von Newcastle-Krankheitvirus

Country Status (12)

Country Link
US (2) US7056689B1 (de)
EP (4) EP1314431B1 (de)
JP (3) JP4338781B2 (de)
AT (3) ATE236271T1 (de)
AU (1) AU699487B2 (de)
CA (1) CA2161671A1 (de)
DE (3) DE69432409T2 (de)
DK (3) DK0696326T5 (de)
ES (3) ES2196026T3 (de)
HK (1) HK1052871A1 (de)
PT (3) PT1486211E (de)
WO (1) WO1994025627A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69432409T2 (de) * 1993-04-30 2003-12-24 Wellstat Biologics Corp Verwendung der NDV zur Herstellung eines Medikaments zur Krebsbehandlung
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
WO2000062735A2 (en) * 1999-04-15 2000-10-26 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
JP2001519175A (ja) 1997-10-09 2001-10-23 プロ − バイラス，インコーポレイテッド ウイルスを用いた新生物の処置
FR2788099B1 (fr) 1999-01-06 2001-02-09 Vallourec Mannesmann Oil & Gas Assemblage filete de deux tubes metalliques a couple eleve de vissage
AU2005201079C1 (en) * 1999-04-15 2008-11-06 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
AU2001279264B2 (en) 2000-06-26 2005-04-28 University Of Ottawa Purging of cells using viruses
AR035227A1 (es) 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
IL157504A0 (en) 2001-05-11 2004-03-28 Wellstat Biologics Corp Oncolytic virus therapy
US7615209B2 (en) * 2001-09-12 2009-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of NDV and methods of use thereof for treatment of cancer
IL145397A0 (en) * 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
CA2374388C (en) 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
US20040005546A1 (en) 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
AU2003243307B2 (en) * 2002-06-21 2010-04-01 Wellstat Biologics Corporation Administration of therapeutic viruses
CA2502890A1 (en) * 2002-11-05 2004-05-27 Wellstat Biologics Corporation Treating carcinoid neoplasms with therapeutic viruses
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
JP2006521383A (ja) * 2003-03-24 2006-09-21 ウェルスタット バイオロジクス コーポレイション 抗癌ウイルス脱感作法
AU2004286144A1 (en) * 2003-11-04 2005-05-12 Dnavec Research Inc. Method for producing gene transferred dendritic cells
WO2005051433A1 (en) * 2003-11-25 2005-06-09 United Cancer Research Institute Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent
US20070207149A1 (en) * 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
KR20070028573A (ko) 2004-06-24 2007-03-12 가부시키가이샤 디나벡크 겐큐쇼 마이너스 가닥 ｒｎａ 바이러스를 포함하는 항암제
ATE540698T1 (de) * 2005-07-14 2012-01-15 Wellstat Biologics Corp Krebsbehandlung mit viren, fluoropyrimidinen und camptothecinen
PL2251034T3 (pl) 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów
US20090175826A1 (en) * 2006-06-05 2009-07-09 Elankumaran Subbiah Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same
US9241998B2 (en) * 2007-05-21 2016-01-26 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oncolytic RSV activity
ES2532808T3 (es) * 2008-09-16 2015-03-31 Genomidea Inc. Agente terapéutico/profiláctico para cáncer de próstata
US8591881B2 (en) 2009-02-05 2013-11-26 Mount Sinai School Of Medicine Chimeric Newcastle disease viruses and uses thereof
DK2327764T3 (da) 2009-11-30 2012-04-02 United Cancer Res Inst Ny klon af Newcastle disease-virus, dens fremstilling og dens anvendelse ved medicinsk behandling af cancer
MA38406B1 (fr) 2013-03-14 2020-03-31 Icahn School Med Mount Sinai Virus de la maladie de newcastle et leurs utilisations
AU2015222685A1 (en) 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
WO2018209052A1 (en) 2017-05-10 2018-11-15 Wellstat Immuno Therapeutics, Llc Enveloped virus resistant to complement inactivation for the treatment of cancer

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577525A (en) 1964-07-01 1971-05-04 Cornell Res Foundation Inc Adenovirus vaccine against canine hepatitis
NL7111160A (de) 1971-03-09 1972-09-12
ZA754725B (en) 1974-08-01 1976-06-30 H Stickl Preparation for the treatment of infectious diseases, method for the manufacture thereof, and its use
JPS5173117A (en) * 1974-12-19 1976-06-24 Handai Biseibutsubyo Kenkyukai Ganryohozaino seiho
US4108983A (en) 1976-06-01 1978-08-22 The Wistar Institute Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors
US4126671A (en) 1976-08-17 1978-11-21 Pitman-Moore, Inc. Method for detecting bovine leukemia viral infection
US4379839A (en) 1977-05-23 1983-04-12 The Trustees Of Columbia University In The City Of New York Method for detecting cancer
IT1117218B (it) 1979-05-18 1986-02-17 Depa Sas Procedimento per la produzione di un prodotto per la diagnosi dei tumori delle parti molli o carcinomi e prodotto ottenuto
US4282315A (en) 1979-09-13 1981-08-04 Corning Glass Works Preparation of enriched whole virus radioligand
US4334016A (en) 1980-06-19 1982-06-08 The Wistar Institute Of Anatomy And Biology Human osteogenic sarcoma cell line and use thereof for immunofluorescent antibody test
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4465769A (en) 1981-12-11 1984-08-14 The United States Of America As Represented By The Department Of Health And Human Services Non-transformed thymidine kinaseless cell line and its use for testing tumorigenic potential of genes
JPS58116422A (ja) 1981-12-28 1983-07-11 Green Cross Corp:The 抗腫瘍剤
US4582787A (en) 1982-12-30 1986-04-15 Frankel Jack W Method of testing a patient for a predisposition to lung cancer, certain other cancers, neurofibromatosis and certain other hereditary disorders
US4571385A (en) 1983-06-27 1986-02-18 The United States Of America As Represented By The Department Of Health And Human Services Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors
US4748109A (en) 1983-07-01 1988-05-31 Baird Phillip J Assay method and reagent to determine antibodies to papillomavirus virions
US4647773A (en) 1984-04-23 1987-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
JPS60249058A (ja) 1984-05-25 1985-12-09 Eisai Co Ltd Ａｔｌウイルス抗体の測定方法および試薬
HU197846B (en) 1984-07-02 1989-06-28 Laszlo Csatary Process for producing therapeutic composition suitable for treating virus infections
US5075213A (en) 1984-07-27 1991-12-24 City Of Hope Method for detection and prevention of human cytomegalovirus infection
HU197517B (en) 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection
FR2593828B2 (fr) 1986-01-31 1990-05-04 Pasteur Institut Sonde a papillomavirus et procede de diagnostic in-vitro d'infections a papillomavirus
US4735895A (en) 1984-12-28 1988-04-05 Oncotech, Inc. Cancer susceptibility test
US4786590A (en) 1985-01-15 1988-11-22 California Institute Of Technology Diagnostic and therapeutic aspects of receptor-mediated leukemogenesis
GB8500918D0 (en) 1985-01-15 1985-02-20 Cancer Res Inst Viral isolates
US4970071A (en) 1985-01-18 1990-11-13 Mcmichael John Immunotherapeutic methods and compositions employing antigens characteristic of non human malignant neoplasms
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
WO1987003451A1 (en) 1985-12-05 1987-06-18 Fred Hutchinson Cancer Research Center Anti-sense rna for treatment of retroviral disease states
AU602875B2 (en) 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
US4839288A (en) 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4861720A (en) 1986-07-03 1989-08-29 Regents Of The University Of California Oncornavirus vaccines and feline alpha-type interferon
NZ224567A (en) * 1987-05-19 1990-08-28 Yissum Res Dev Co Vaccine against newcastle disease virus comprising a live immunogenic lentogenic or mesogenic strain of newcastle disease virus in combination with a liquid containing a mineral or vegetable oil
US4849334A (en) 1987-06-09 1989-07-18 Life Technologies, Inc. Human papillomavirus 43 nucleic acid hybridization probes and methods for employing the same
US4908306A (en) 1987-06-12 1990-03-13 Life Technologies, Inc. Human papillomavirus 56 nucleic acid hybridization probes and methods for employing the same
DE3722968A1 (de) 1987-07-11 1989-01-19 Behringwerke Ag Humaner papillomvirus typ 41, seine dna und die dafuer kodierenden proteine
CA1341439C (en) 1987-08-26 2003-09-23 Niels C. Pedersen Feline t-lymphotropic lentivirus
DE68929343T2 (de) 1988-02-16 2002-09-12 Greatbatch Gen Aid Ltd Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen
DE3806565A1 (de) 1988-03-01 1989-09-14 Deutsches Krebsforsch Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
US5077198A (en) 1988-04-14 1991-12-31 Eastman Kodak Company Diagnostic kit and method for rapid detection of antibodies
US5215745A (en) 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5124148A (en) 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
FR2632956B2 (fr) 1988-05-13 1991-07-12 Pasteur Institut Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus
US5192539A (en) 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
US5057314A (en) 1988-09-30 1991-10-15 Whitfill Craig E Low molecular weight antiviral factors
FR2639225B1 (fr) 1988-11-21 1993-05-21 Centre Nat Rech Scient Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
US5045447A (en) 1989-03-15 1991-09-03 Minson Anthony C Method of producing antibodies to HPV
US5169753A (en) 1989-06-05 1992-12-08 Genelabs Incorporated Method and kit for detecting human retrovirus
FR2656627B1 (fr) 1989-12-28 1992-04-17 Pasteur Institut Sonde a papillomavirus (hvpv63), notamment pour le diagnostic in vitro d'infections a papillomavirus, pouvant s'accompagner de neoplasies genitales, et produits genetiquement et immunologiquement lies a ce papillomavirus.
CN1054192A (zh) * 1990-02-26 1991-09-04 张炳团 人体内诱导干扰素的制造方法
US5739107A (en) * 1991-03-11 1998-04-14 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5195539A (en) * 1992-03-23 1993-03-23 Minnesota Mining And Manufacturing Company Earplug compression device
PT713397E (pt) 1992-03-24 2003-04-30 United Cancer Res Inst Vacina que contem virus vivos
DE69426841T2 (de) 1993-02-16 2001-09-06 Onyx Pharma Inc Cytopatische Viren zur Therapie und Prophylaxe der Neoplasie
KR960701208A (ko) 1993-03-16 1996-02-24 엔 엔 데이비스 바이러스 단백질에 의해 면역 반응을 자극하는 방법(stimulation of immune response by viral protein)
DE69432409T2 (de) * 1993-04-30 2003-12-24 Wellstat Biologics Corp Verwendung der NDV zur Herstellung eines Medikaments zur Krebsbehandlung
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
CA2502890A1 (en) * 2002-11-05 2004-05-27 Wellstat Biologics Corporation Treating carcinoid neoplasms with therapeutic viruses

Also Published As

Publication number Publication date
DE69432409D1 (de) 2003-05-08
ES2315595T3 (es) 2009-04-01
PT696326E (pt) 2003-08-29
DK0696326T5 (da) 2003-07-14
EP1486211A1 (de) 2004-12-15
EP1314431A3 (de) 2003-06-18
JP2009149689A (ja) 2009-07-09
US7736640B2 (en) 2010-06-15
ATE401092T1 (de) 2008-08-15
AU699487B2 (en) 1998-12-03
HK1052871A1 (zh) 2003-10-03
JP2005187484A (ja) 2005-07-14
JP4338781B2 (ja) 2009-10-07
ES2310580T3 (es) 2009-01-16
EP1314431A2 (de) 2003-05-28
DK0696326T3 (da) 2003-06-23
ATE236271T1 (de) 2003-04-15
US20060216310A1 (en) 2006-09-28
PT1314431E (pt) 2008-10-24
AU6821394A (en) 1994-11-21
EP2009119A1 (de) 2008-12-31
PT1486211E (pt) 2009-02-02
CA2161671A1 (en) 1994-11-10
DK1314431T3 (da) 2008-11-10
DK1486211T3 (da) 2009-01-19
EP1486211B1 (de) 2008-10-22
ES2196026T3 (es) 2003-12-16
EP0696326B1 (de) 2003-04-02
WO1994025627A1 (en) 1994-11-10
EP0696326A4 (de) 1997-08-20
EP0696326A1 (de) 1996-02-14
US7056689B1 (en) 2006-06-06
DE69435118D1 (de) 2008-08-28
ATE411809T1 (de) 2008-11-15
JPH09503995A (ja) 1997-04-22
DE69432409T2 (de) 2003-12-24
EP1314431B1 (de) 2008-07-16

Similar Documents

Publication Publication Date Title
DE69435155D1 (de) Zusuammensetzungen zur Behandlung von Krebs mittels Viren
DE69430611D1 (de) Phosphonooxymethyl oder Methylthiomethylether von Taxanderivaten als Antitumormittel
PT842934E (pt) Agonistas de 5-ht1f
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
DK0791571T3 (da) Benzoylderivater
EA200300023A1 (ru) 3'-ПРОЛЕКАРСТВА 2'-ДЕЗОКСИ-β-L-НУКЛЕОЗИДОВ
ATE231839T1 (de) Polyaromatische antivirale zusammensetzungen
ES2058815T3 (es) Composiciones farmaceuticas para el tratamiento de desarreglos gastrointestinales.
ATE265535T1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
DE69902526D1 (de) Verbesserung der antibakteriellen wirkung von oxazolidinon durch arginin derivate
DE69835536D1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
ES2079068T3 (es) 2-amino-6-fenil-4h-piran-4-onas antiateroscleroticas y antitromboticas.
FI961380A0 (fi) Koostumuksia virusten aiheuttamien kasvainten ehkäisemiseksi ja hoitamiseksi
ID25478A (id) Agonis 5-ht1f
SE8303886L (sv) Synergetisk antihypertensiv farmaceutisk komposition
EA200001065A1 (ru) Применение фосфорорганических соединений для терапевтического и профилактического лечения инфекций

Legal Events

Date Code Title Description
8364 No opposition during term of opposition